Medicalisation, limits to medicine, or never enough money to go around?
作者信息
Freemantle Nick, Hill Suzanne
出版信息
BMJ. 2002 Apr 13;324(7342):864-5. doi: 10.1136/bmj.324.7342.864.
Abstract
摘要
相似文献
1
Medicalisation, limits to medicine, or never enough money to go around?医学化、医学的局限性，还是资金总是不够用？
BMJ. 2002 Apr 13;324(7342):864-5. doi: 10.1136/bmj.324.7342.864.
2
Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.复方制剂：中低收入国家预防心血管疾病的一种经济可行策略。
Ther Adv Cardiovasc Dis. 2018 Jun;12(6):169-174. doi: 10.1177/1753944718764588. Epub 2018 Mar 16.
3
Physician opinion on the secondary prevention of stroke: results of a survey in New Zealand.新西兰医生对中风二级预防的看法：一项调查结果
Cerebrovasc Dis. 2000 May-Jun;10(3):244-6. doi: 10.1159/000016064.
4
TIAs - management in general practice.
Aust Fam Physician. 2010 Nov;39(11):813.
5
Low-density-lipoprotein cholesterol in patients treated by a lipid clinic versus a primary care clinic.脂质门诊与初级保健门诊治疗患者的低密度脂蛋白胆固醇情况
Am J Health Syst Pharm. 2000 Dec 15;57(24):2285-6. doi: 10.1093/ajhp/57.24.2285.
6
D-003.D - 003
Drugs R D. 2002;3(5):349. doi: 10.2165/00126839-200203050-00009.
7
How drug prices are set: an example from the perspective of a social security association.药品价格是如何制定的：以一个社会保障协会的视角为例。
Clin Pharmacol Ther. 2002 Jul;72(1):101-3. doi: 10.1067/mcp.2002.125901.
8
Controversies in dyslipidaemia management.血脂异常管理中的争议
Atherosclerosis. 2012 Apr;221(2):321-4. doi: 10.1016/j.atherosclerosis.2011.12.036. Epub 2012 Jan 8.
9
Controversies in hyperlipidaemia: issues resolved?高脂血症中的争议：问题解决了吗？
Br J Hosp Med. 1996;56(11):566-7.
10
The use of statins: a case of misleading priorities?他汀类药物的使用：一个优先事项被误导的案例？
BMJ. 1997 Oct 4;315(7112):826-8. doi: 10.1136/bmj.315.7112.826.
引用本文的文献
1
Views on primary prevention of cardiovascular disease--an interview study with Swedish GPs.心血管疾病一级预防观点——对瑞典全科医生的访谈研究。
BMC Fam Pract. 2010 Jun 2;11:44. doi: 10.1186/1471-2296-11-44.
2
Combating disease mongering: daunting but nonetheless essential.对抗疾病兜售行为：艰巨但必不可少。
PLoS Med. 2006 Apr;3(4):e146. doi: 10.1371/journal.pmed.0030146. Epub 2006 Apr 11.
3
Who needs health care--the well or the sick?谁需要医疗保健——健康的人还是生病的人？
BMJ. 2005 Apr 23;330(7497):954-6. doi: 10.1136/bmj.330.7497.954.
4
On professionalism.论职业精神。
Br J Gen Pract. 2003 Dec;53(497):991.
5
Desert docs.沙漠医生。
Br J Gen Pract. 2003 Dec;53(497):988-9.
6
Postcard 6... Community care. Social entrepreneurs are creating better communities.明信片6……社区关怀。社会企业家正在打造更美好的社区。
Br J Gen Pract. 2003 Dec;53(497):986-7.
7
Hippocrates appraises 21st century doctors.希波克拉底评价21世纪的医生。
Br J Gen Pract. 2003 Dec;53(497):984-5.
8
Reflections on annual appraisal.关于年度评估的思考
Br J Gen Pract. 2003 Dec;53(497):982.
9
Worth doing badly? Sexual health promotion in primary care.做得不好也值得做？初级保健中的性健康促进。
Br J Gen Pract. 2003 Dec;53(497):981.
10
[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].[西立伐他汀相关性横纹肌溶解症的临床药理学解释模型]
Wien Med Wochenschr. 2003;153(11-12):250-4. doi: 10.1046/j.1563-258x.2003.03029.x.
本文引用的文献
1
Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey.美国非卧床成年人群近期的用药模式：斯隆调查
JAMA. 2002 Jan 16;287(3):337-44. doi: 10.1001/jama.287.3.337.
2
Pricing and reimbursement of pharmaceuticals in the Baltic States.波罗的海国家药品的定价与报销
Lancet. 2001 Jul 28;358(9278):260. doi: 10.1016/S0140-6736(01)05496-4.
3
Access to essential drugs in poor countries: a lost battle?贫困国家获取基本药物：一场失败的战斗？
JAMA. 1999 Jan 27;281(4):361-7. doi: 10.1001/jama.281.4.361.
4
Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed.
BMJ. 1998 Apr 18;316(7139):1241-2.
5
The use of statins: a case of misleading priorities?他汀类药物的使用：一个优先事项被误导的案例？
BMJ. 1997 Oct 4;315(7112):826-8. doi: 10.1136/bmj.315.7112.826.
6
7
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.普伐他汀预防高胆固醇血症男性冠心病。苏格兰西部冠心病预防研究组。
N Engl J Med. 1995 Nov 16;333(20):1301-7. doi: 10.1056/NEJM199511163332001.
Zotero 插件